{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:23:57Z","timestamp":1790843037527,"version":"4.1.0"},"reference-count":38,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec id=\"S1092852917000232_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating major depressive disorder (MDD) with mixed features including irritability.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000232_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>The data in this analysis were derived from a study of patients meeting DSM\u2013IV\u2013TR criteria for unipolar MDD, with a Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS) total score \u226526, presenting with two or three protocol-defined manic symptoms, and who were randomized to 6 weeks of double-blind treatment with either lurasidone 20\u201360 mg\/d (<jats:italic>n<\/jats:italic>=109) or placebo (<jats:italic>n<\/jats:italic>=100). We defined \u201cirritability\u201d as a score \u22652 on both the Young Mania Rating Scale (YMRS) irritability item (#5) and the disruptive-aggressive item (#9). Endpoint change in the MADRS and YMRS items 5 and 9 were analyzed using a mixed model for repeated measures for patients with and without irritability.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000232_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Some 20.7% of patients met the criteria for irritability. Treatment with lurasidone was associated with a significant week 6 change vs. placebo in MADRS score in both patients with (\u201322.6 vs. \u20139.5,<jats:italic>p<\/jats:italic>&lt;0.0001, effect size [<jats:italic>ES<\/jats:italic>]=1.4) and without (\u201319.9 vs. \u201313.8,<jats:italic>p<\/jats:italic>&lt;0.0001,<jats:italic>ES<\/jats:italic>=0.7) irritability. In patients with irritable features, treatment with lurasidone was associated with significant week 6 changes vs. placebo in both the YMRS irritability item (\u20131.4 vs. \u20130.3,<jats:italic>p<\/jats:italic>=0.0012,<jats:italic>ES<\/jats:italic>=1.0) and the YMRS disruptive-aggressive item (\u20131.0 vs. \u20130.3,<jats:italic>p<\/jats:italic>=0.0002,<jats:italic>ES<\/jats:italic>=1.2).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000232_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>In our post-hoc analysis of a randomized, placebo-controlled, 6-week trial, treatment with lurasidone significantly improved depressive symptoms in MDD patients with mixed features including irritability. In addition, irritability symptoms significantly improved in patients treated with lurasidone.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852917000232","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T16:20:17Z","timestamp":1489681217000},"page":"228-235","source":"Crossref","is-referenced-by-count":14,"title":["Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis"],"prefix":"10.1017","volume":"22","author":[{"given":"Alan C.","family":"Swann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcai","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"key":"S1092852917000232_ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000086321"},{"key":"S1092852917000232_ref13","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000364"},{"key":"S1092852917000232_ref1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1998)8:1+<59::AID-DA9>3.0.CO;2-Y"},{"key":"S1092852917000232_ref27","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070984"},{"key":"S1092852917000232_ref25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10060907"},{"key":"S1092852917000232_ref24","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04905"},{"key":"S1092852917000232_ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-016-0056-2"},{"key":"S1092852917000232_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01298.x"},{"key":"S1092852917000232_ref29","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15060770"},{"key":"S1092852917000232_ref3","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0818a"},{"key":"S1092852917000232_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.07.006"},{"key":"S1092852917000232_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.09.016"},{"key":"S1092852917000232_ref6","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2009.20"},{"key":"S1092852917000232_ref31","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S1092852917000232_ref2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0202"},{"key":"S1092852917000232_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.1957"},{"key":"S1092852917000232_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.12.046"},{"key":"S1092852917000232_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00332-4"},{"key":"S1092852917000232_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.03.013"},{"key":"S1092852917000232_ref23","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"S1092852917000232_ref8","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"S1092852917000232_ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.179"},{"key":"S1092852917000232_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.11.024"},{"key":"S1092852917000232_ref28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070985"},{"key":"S1092852917000232_ref33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"S1092852917000232_ref17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2010.09071011"},{"key":"S1092852917000232_ref38","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09719"},{"key":"S1092852917000232_ref22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09092"},{"key":"S1092852917000232_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2004.07.004"},{"key":"S1092852917000232_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2005.07.024"},{"key":"S1092852917000232_ref32","doi-asserted-by":"crossref","unstructured":"Guy W . ECDEU Assessment Manual for Psychopharmacology. Publication no. ADM 76\u2013338. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976: esp. 218\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"S1092852917000232_ref37","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10470"},{"key":"S1092852917000232_ref18","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.87"},{"key":"S1092852917000232_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.09.026"},{"key":"S1092852917000232_ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2011.00957.x"},{"key":"S1092852917000232_ref36","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315618621"},{"key":"S1092852917000232_ref30","volume-title":"Structured Clinical Interview for DSM\u2013IV\u2013TR Axis I Disorders, Clinical Trials Version (SCID\u2013CT)","author":"First","year":"2007"},{"key":"S1092852917000232_ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01324.x"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852917000232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T20:57:55Z","timestamp":1568926675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852917000232\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1092852917000232"],"URL":"https:\/\/doi.org\/10.1017\/s1092852917000232","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}